These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 35677036)

  • 1. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-β Score based on
    Zhang W; Yan Z; Zhao F; He Q; Xu H
    Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
    Tan S; Spear R; Zhao J; Sun X; Wang P
    Front Genet; 2022; 13():905047. PubMed ID: 35832194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
    Chen J; Li Y; Han X; Pan Y; Qian X
    Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment.
    Zhu L; Yuan F; Wang X; Zhu R; Guo W
    Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
    Wu S; Miao K; Wang L; Ma Y; Wu X
    Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cuproptosis-based prognostic model for predicting survival in low-grade glioma.
    Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J
    Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
    Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
    Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a glioma prognostic model based on telomere-related genes and immune infiltration analysis.
    Liu X; Wang J; Su D; Wang Q; Li M; Zuo Z; Han Q; Li X; Zhen F; Fan M; Chen T
    Transl Cancer Res; 2024 Jul; 13(7):3182-3199. PubMed ID: 39145097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.